This site is intended for UK healthcare professionals

 
This promotional video has been developed, organised, and funded by Novartis Pharmaceuticals. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.

Click here to access ENTRESTO® (sacubitril/valsartan) prescribing information.
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction1
Adverse events reporting information can be found at the bottom of the page.
novartis-logo-transparent
04:02

Heart Failure Foundation Course: Pharmacological and non-pharmacological approaches to the management of heart failure and the role of devices

1 August 2024

Sponsored

04:02
In this summary video, Rhys Williams (Clinical Pharmacist, Princess of Wales Hospital, South Wales) provides an overview of the four pillars of heart failure therapy, the European Society of Cardiology guidelines for heart failure with reduced ejection fraction, and the role of devices in heart failure management.

To watch the full on-demand video and other videos in this series click here (this will direct to Novartis promotional content).


Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370. 

References

  1. ENTRESTO® (sacubitril/valsartan) Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/3124
 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

BJC TV

To continue, please confirm that you are a UK healthcare professional.